July 29 -- Kunming Pharmaceutical (600422) reported that its revenue rose 27.92 percent to 1.076 billion yuan, while net profit rose and 73.69 percent to 56.01 million yuan in the first half of 2011, reports China Business News, citing a company filing.

An analyst from Guosen Securities believes Kunming Pharmaceutical’s major products, including Xuesaitong and Gestrodin brand injections as well as the Xuesaitong soft capsule were the main net profit contributors during the reporting period.

Also, the performance of Kuming Chinese Medicine Factory, the listed company’s subsidy, is expected to improve after adjusting its marketing department. Kunming Pharmaceutical’s joint venture, Kunming Baker Norton, will continue to introduce new medicines from the overseas clients.

In the second half of 2011, the Yunnan province-based company will accelerate work on the promotion of oral preparations.

Source:CapitalVue